Cardiology – Medxy AI

LOXL2 Inhibition: A New Frontier in Treating LMNA-Related Dilated Cardiomyopathy

By MedXY 03/17/2026

Recent research identifies LOXL2 as a primary driver of fibrosis in LMNA-mutated dilated cardiomyopathy. The study demonstrates that Simtuzumab, a LOXL2 inhibitor, effectively prevents extracellular matrix remodeling and preserves cardiac function in both human iPSC and murine models.

Cardiology Clinical Updates Diabetes & Endocrinology Internal Medicine news

The Rising Tide of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Synthesis of Medication Eligibility and Clinical Implementation

By MedXY 03/17/2026

This review synthesizes population-level data on the eligibility for GLP-1RAs, SGLT2is, and nsMRAs, highlighting that over 60% of US adults meet indications for these transformative therapies.

Cardiology news

Transcatheter Edge-to-Edge Repair Superior to Medical Therapy in Atrial Functional Mitral Regurgitation: Evidence from Real-World Registries

By MedXY 03/17/2026

A propensity score-based study demonstrates that transcatheter edge-to-edge repair (TEER) significantly reduces mortality and heart failure hospitalizations in patients with atrial functional mitral regurgitation compared to medical therapy, especially when achieving low residual regurgitation.

Cardiology Clinical Updates news

Mapping the Plasma Proteome to Predict Venous Thromboembolism: Evidence from Multi-Cohort Proteomic Profiling and Causal Inference

By MedXY 03/17/2026

This review synthesizes cutting-edge findings from multi-ethnic longitudinal cohorts using high-throughput proteomics to identify novel biomarkers and causal pathways for venous thromboembolism, moving beyond traditional clotting factors.

Cardiology news

TAVI Superiority in Women with Aortic Stenosis: New Evidence from the DEDICATE-DZHK6 Trial

By MedXY 03/17/2026

A subgroup analysis of the DEDICATE-DZHK6 trial reveals that TAVI significantly reduces the 1-year risk of death or stroke compared to SAVR in both sexes, with particularly pronounced clinical benefits for women, especially regarding stroke prevention.

Cardiology Internal Medicine news

Coronary Artery Calcium Scoring Remains the Definitive Risk Stratifier for Patients With Elevated Lipoprotein(a)

By MedXY 03/17/2026

A large multicohort study involving 11,319 participants confirms that Coronary Artery Calcium (CAC) scoring effectively stratifies cardiovascular risk even in individuals with high Lipoprotein(a), providing clinical clarity for personalized preventive strategies and the management of primary prevention patients.

Cardiology Internal Medicine news

CRLF1 Secreted by Cardiac Fibroblasts: A New Driver and Potential Therapeutic Target for Hypertrophic Cardiomyopathy

By MedXY 03/17/2026

This article explores a groundbreaking study identifying CRLF1, a protein secreted by cardiac fibroblasts, as a key driver of Hypertrophic Cardiomyopathy (HCM). This paracrine signaling mechanism offers a potential universal therapeutic target for patients regardless of their specific genetic mutations.

Cardiology Clinical Updates news

Interaction Between SGLT2 Inhibition and Dietary Sodium: Insights from the CREDENCE Trial Post Hoc Analysis

By MedXY 03/15/2026

This post hoc analysis of the CREDENCE trial reveals that low-normal sodium intake increases cardiovascular risk in T2D and CKD, a risk significantly mitigated by canagliflozin, while renal protection remains consistent across sodium intake levels.

Cardiology Diabetes & Endocrinology news

Chronic Inflammation via suPAR: The Missing Link Between Diabetes and Cardiovascular Mortality

By MedXY 03/15/2026

A landmark study in Diabetes Care reveals that soluble urokinase plasminogen activator receptor (suPAR) mediates over half of the increased risk for adverse cardiovascular outcomes in patients with diabetes and coronary artery disease, surpassing traditional inflammatory markers like hs-CRP.

Cardiology Clinical Updates Diabetes & Endocrinology news

The Changing Landscape of Mortality in Diabetes: A Shift from Cardiovascular Dominance to Cancer and Dementia

By MedXY 03/14/2026

This review analyzes multinational data showing a significant decline in cardiovascular mortality among diabetes patients, alongside a concerning rise in dementia-related deaths and the emergence of cancer as a leading cause of mortality in high-income settings.

Cardiology Clinical Updates news

Residual Clinical Risk and Economic Burden in HFrEF: Insights from the Quadruple Medical Therapy Era

By MedXY 03/14/2026

This review analyzes the real-world one-year outcomes and healthcare costs for HFrEF patients on quadruple therapy, revealing significant residual risk despite optimized pharmacologic management.

Cardiology news

Moderate Mixed Aortic Valve Disease: Why Moderate Severity Carries Severe Risk

By MedXY 03/14/2026

A large-scale multicenter study demonstrates that moderate mixed aortic valve disease (MAVD) carries a mortality risk comparable to severe aortic stenosis when symptoms or left ventricular dysfunction are present, challenging current guideline-based management for these patients.

Cardiology news

Efficiency Unleashed: Real-Time Heart Teams Transform Complex CAD Management in the EHEART Trial

By MedXY 03/14/2026

The EHEART trial reveals that real-time, online heart team discussions during angiography significantly improve clinical efficiency and reduce costs for complex CAD patients, while maintaining 1-year safety outcomes noninferior to traditional face-to-face multidisciplinary meetings.

Cardiology Clinical Updates Diabetes & Endocrinology news

Adipocyte-Cardiomyocyte Communication via Surface-Bound Adiponectin: Mechanisms of sEV Failure in Diabetic Ischemic Heart Failure

By MedXY 03/14/2026

This review explores how adipocyte-derived small extracellular vesicles (sEVs) use surface-bound adiponectin to protect the heart, and how diabetes-induced GRK2 upregulation disrupts this vital signaling pathway, leading to ischemic heart failure.

Cardiology news Otorhinolaryngology Pediatrics

A New Standard for Pediatric Vocal Fold Immobility After Cardiac Surgery: Improving Outcomes Through Injection Laryngoplasty

By MedXY 03/13/2026

Recent research highlights a standardized multidisciplinary protocol for managing unilateral vocal fold immobility in infants after cardiothoracic surgery, showing that injection laryngoplasty significantly improves oral feeding advancement and reduces dependence on feeding tubes.

Cardiology Hematology-Oncology news

Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation

By MedXY 03/12/2026

A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populations.

Cardiology news Oncology

Optimized Heart Failure Therapy in Advanced Cancer: Insights from the EMPATICC Trial

By MedXY 03/12/2026

The EMPATICC trial explored heart failure therapy for patients with advanced cancer in palliative care. While it did not meet its primary endpoint for self-care ability due to high mortality, survivors showed improved cardiac biomarkers and well-being, suggesting potential for individualized cardio-oncology interventions.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events

By MedXY 03/12/2026

This emulation study applies SELECT trial data to over 600,000 individuals, suggesting that GLP-1RAs could significantly reduce 10-year cardiovascular risk in high-risk obese populations without existing disease, offering a potential 22% relative risk reduction.

Cardiology Internal Medicine news

TRIM28: A Novel E3 Ubiquitin Ligase Guarding the Heart Against Ischemia/Reperfusion-Induced Ferroptosis

By MedXY 03/12/2026

New research identifies TRIM28 as a critical E3 ubiquitin ligase that degrades IRP2, thereby suppressing iron uptake and preventing myocardial ferroptosis during ischemia/reperfusion injury. This pathway, activated by p55γ and the drug perhexiline, offers a promising therapeutic target for patients with ischemic heart disease.

Cardiology Diabetes & Endocrinology news

Tirzepatide Outperforms Dulaglutide in Cardiovascular Risk Reduction: Insights from Real-World Target-Trial Emulations

By MedXY 03/11/2026

A large-scale target-trial emulation study reveals that tirzepatide significantly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality compared to dulaglutide in patients with type 2 diabetes and ASCVD, while performing similarly to semaglutide.